The Position:

We are seeking a highly talented, creative and motivated candidate for a Postdoctoral position in the laboratory of Felipe de Sousa e Melo at the department of Discovery Oncology. The successful candidate will have access to a broad range of technologies to investigate how dysregulation of key oncogenes contribute to colon cancer development, progression and resistance to therapies. Candidates with a good understanding of the mechanistic process that drive cancer progression and/or experience primary/3D culture system to study pathways involved in tumor cell growth are encouraged to apply. This is an ideal position for someone who enjoys the translational aspects of converting basic biology discoveries in cancer development into drug discovery programs and who thrives in a team environment.

Who You Are:

• Qualified candidates will hold a doctoral degree in Cell Biology, Molecular Biology, or Biochemistry and have a successful track record as illustrated by a publication record

• Proficiency in a broad range of biochemical, molecular, and cell biological techniques.

• Key technical skills include:

o Primary organoid engineering using both lentiviral and CRISPR-based approaches.

o Functional genomic screening techniques, both RNAi and CRISPR.

o Cell proliferation assays

o Biochemical techniques including western blotting, co-immunoprecipitation, and in vitro assays using purified components.

• Good organizational, problem-solving, and verbal/written communication skills.

• Ability and desire to work both independently and collaboratively in a dynamic research environment.

For immediate consideration please email your CV to Felipe de Sousa e Melo at desousaf@gene.com

About the Lab:

Dr. de Sousa e Melo is currently a group lead and Senior Principal Scientist at Genentech. He leads a discovery research group operating at the interface between technology and biology with specific emphasis on colorectal cancer biology. More recently, his lab has devised a technology that exploits the elevated expression of the cell surface E3 ubiquitin ligases ZNRF3 and RNF43 in colon cancer. More specifically, his team has generated bispecific antibodies that can tether these E3 ubiquitin ligases to a variety of cell surface receptors to promote tumor receptor degradation. This platform that has been dubbed PROTABs for Proteolysis Targeting Antibodies. The in vivo bioavailability and tumor specificity of this approach makes it potentially attractive for the therapeutic management of colon cancer.

Relocation benefits are available for this position

The expected salary range for this position based on the primary location of California is $64,800 and $120,500.  Actual pay will be determined based on experience, qualifications, geographic location, and other job-related factors permitted by law.  This position also qualifies for the benefits detailed at the link provided below.

Benefits

Genentech is an equal opportunity employer, and we embrace the increasingly diverse world around us. Genentech prohibits unlawful discrimination based on race, color, religion, gender, sexual orientation, gender identity or expression, national origin or ancestry, age, disability, marital status and veteran status.

Genentech requires all new hires to be fully vaccinated against COVID-19 as of their start date. This requirement is a condition of employment at Genentech, and it applies regardless of whether the position is located at a Genentech campus or is fully remote.  If you are unable to receive the vaccine due to a disability or serious medical condition, or because it is prohibited as a result of your sincerely held religious beliefs, you will have an opportunity to request a reasonable accommodation.